These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 22735608)

  • 1. A combination of faecal tests for the detection of colon cancer: a new strategy for an appropriate selection of referrals to colonoscopy? A prospective multicentre Italian study.
    Parente F; Marino B; Ilardo A; Fracasso P; Zullo A; Hassan C; Moretti R; Cremaschini M; Ardizzoia A; Saracino I; Perna F; Vaira D
    Eur J Gastroenterol Hepatol; 2012 Oct; 24(10):1145-52. PubMed ID: 22735608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between Faecal Tumour M2 Pyruvate Kinase and Colonoscopy for the Detection of Adenomatous Neoplasia in a Secondary Care Cohort.
    Bond AD; Burkitt MD; Sawbridge D; Corfe BM; Probert CS
    J Gastrointestin Liver Dis; 2016 Mar; 25(1):71-7. PubMed ID: 27014756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of faecal protein biomarkers' diagnostic accuracy for colorectal advanced neoplasms: a systematic review and meta-analysis.
    Nasir Kansestani A; Zare ME; Tong Q; Zhang J
    Sci Rep; 2022 Feb; 12(1):2623. PubMed ID: 35173276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer.
    Mulder SA; van Leerdam ME; van Vuuren AJ; Francke J; van Toorenenbergen AW; Kuipers EJ; Ouwendijk RJ
    Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):878-82. PubMed ID: 17873612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma.
    Tibble J; Sigthorsson G; Foster R; Sherwood R; Fagerhol M; Bjarnason I
    Gut; 2001 Sep; 49(3):402-8. PubMed ID: 11511563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of faecal M2-PK and FIT in a population-based bowel cancer screening cohort.
    Leen R; Seng-Lee C; Holleran G; O'Morain C; McNamara D
    Eur J Gastroenterol Hepatol; 2014 May; 26(5):514-8. PubMed ID: 24699725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Power of screening tests for colorectal cancer enhanced by high levels of M2-PK in addition to FOBT.
    Zaccaro C; Saracino IM; Fiorini G; Figura N; Holton J; Castelli V; Pesci V; Gatta L; Vaira D
    Intern Emerg Med; 2017 Apr; 12(3):333-339. PubMed ID: 28155016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Faecal biomarkers do not always identify pre-cancerous lesions in patients who present in primary care with bowel symptoms.
    Keenan J; Aitchison A; Leaman J; Pearson J; Frizelle F
    N Z Med J; 2019 Aug; 132(1501):48-56. PubMed ID: 31465327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis.
    Tonus C; Sellinger M; Koss K; Neupert G
    World J Gastroenterol; 2012 Aug; 18(30):4004-11. PubMed ID: 22912551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study.
    Shastri YM; Loitsch S; Hoepffner N; Povse N; Hanisch E; Rösch W; Mössner J; Stein JM
    Am J Gastroenterol; 2008 Jun; 103(6):1496-504. PubMed ID: 18510609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of faecal calprotectin in the identification of colorectal neoplasia in patients attending for screening colonoscopy.
    Ross FA; Park JH; Mansouri D; Little C; Di Rollo DG; Combet E; Van Wyk H; Horgan PG; McMillan DC; Roxburgh CSD
    Colorectal Dis; 2022 Feb; 24(2):188-196. PubMed ID: 34614299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Detection of Colorectal Cancer: a Multi-Center Pre-Clinical Case Cohort Study for Validation of a Combined DNA Stool Test.
    Dollinger MM; Behl S; Fleig WE
    Clin Lab; 2018 Oct; 64(10):1719-1730. PubMed ID: 30336540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of immunochemical faecal occult blood test in colorectal cancer screening in average-risk population according to positivity threshold and number of samples.
    Guittet L; Bouvier V; Mariotte N; Vallee JP; Levillain R; Tichet J; Launoy G
    Int J Cancer; 2009 Sep; 125(5):1127-33. PubMed ID: 19431212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Usefulness of a Novel Screening Kit for Colorectal Cancer Using the Immunochromatographic Fecal Tumor M2 Pyruvate Kinase Test.
    Kim YC; Kim JH; Cheung DY; Kim TH; Jun EJ; Oh JW; Kim CW; Chung WC; Kim BW; Kim SS; Kim JI; Park SH; Kim JK
    Gut Liver; 2015 Sep; 9(5):641-8. PubMed ID: 25473070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of advanced colonic neoplasm in symptomatic patients: a scoring system to prioritize colonoscopy (COLONOFIT study).
    Fernández-Bañares F; Clèries R; Boadas J; Ribes J; Oliva JC; Alsius A; Sanz X; Martínez-Bauer E; Galter S; Pujals M; Pujol M; Del Pozo P; Campo R
    BMC Cancer; 2019 Jul; 19(1):734. PubMed ID: 31345180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosing colorectal cancer and inflammatory bowel disease in primary care: The usefulness of tests for faecal haemoglobin, faecal calprotectin, anaemia and iron deficiency. A prospective study.
    Högberg C; Karling P; Rutegård J; Lilja M
    Scand J Gastroenterol; 2017 Jan; 52(1):69-75. PubMed ID: 27623716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Faecal haemoglobin can define risk of colorectal neoplasia at surveillance colonoscopy in patients at increased risk of colorectal cancer.
    Digby J; Cleary S; Gray L; Datt P; Goudie DR; Steele RJC; Strachan JA; Humphries A; Fraser CG; Mowat C
    United European Gastroenterol J; 2020 Jun; 8(5):559-566. PubMed ID: 32213041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase.
    Caviglia GP; Cabianca L; Fagoonee S; Gili FM
    Biochem Med (Zagreb); 2016; 26(1):114-20. PubMed ID: 26981025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controversies in colorectal cancer screening.
    Pox CP
    Digestion; 2014; 89(4):274-81. PubMed ID: 25034478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT).
    Hoff G; Grotmol T; Thiis-Evensen E; Bretthauer M; Gondal G; Vatn MH
    Gut; 2004 Sep; 53(9):1329-33. PubMed ID: 15306594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.